Press Releases

November 4, 2024

New Findings by Friends of Cancer Research HRD Harmonization Project Published in JCO Oncology Advances

Findings by Friends of Cancer Research (Friends) and collaborators were published today in JCO Oncology Advances, “An Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings from the Friends’ HRD Harmonization Project.” This manuscript examines variability in outputs from HRD assays assessing a common sample set. HRD is a biomarker used to determine eligibility for Poly ADP-ribose Polymerase Inhibitors (PARPi) to treat patients with high-grade serous ovarian carcinoma…

August 19, 2024

New Findings by Friends of Cancer Research RWE Portfolio Published in JCI Clinical Cancer Informatics

New findings by Friends of Cancer Research (Friends) were published recently in JCO Clinical Cancer Informatics “Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in mNSCLC patients treated with chemotherapy.” This salient publication demonstrates the feasibility of aligning disparate real-world (rw) data sources to evaluate rw-response to treatment…

July 18, 2024

NIH Director Monica Bertagnolli and Congressman Brett Guthrie to Receive the 2024 Cancer Leadership Awards

Friends of Cancer Research (Friends) is proud to announce our 2024 Cancer Leadership Award recipients: Director of the National Institutes of Health, Dr. Monica Bertagnolli, and U.S. Representative for Kentucky’s 2nd congressional district, the Honorable Brett Guthrie. These two extraordinary leaders will be honored on September 19, 2024, in Washington, DC. Dr. Monica Bertagnolli will…

June 17, 2024

New Publication: An evaluation of novel oncology approvals with a PMR/C for assessing data in racial and ethnic populations underrepresented in premarket clinical trials

A new publication by Friends of Cancer Research (Friends) was published in Clinical Cancer Research, a journal of the American Association for Cancer Research, “An evaluation of novel oncology approvals with a PMR/C for assessing data in racial and ethnic populations underrepresented in premarket clinical trials.” This important publication used publicly available data to…

May 7, 2024

New Manuscript Provides Evidence and Key Considerations for the Use of ctDNA in Oncology

Washington, DC – May 7, 2024 – A new publication by Friends of Cancer Research (Friends) was recently published in the journal Diagnostics: “Advancing Evidence Generation for ctDNA: Lessons Learned from A Multi-Assay Study of Baseline ctDNA Levels Across Cancer Types and Stages.” This collaborative publication evaluates circulating tumor DNA (ctDNA) levels prior to cancer…

April 10, 2024

New Publication Outlines a Framework to Support More Efficient Clinical Development Programs

A new publication by Friends of Cancer Research (Friends) was published in Cytotherapy, “Accelerated Development of Genetically Engineered Cellular Therapies: A Framework for Extrapolating Data Across Related Products.” This exciting manuscript examines the current opportunities and challenges with development approaches of genetically engineered cellular therapies to propose solutions to optimize development. The publication outlines a…

March 22, 2024

Jeff Allen Testifies Before the U.S. House of Representatives Committee on Energy and Commerce

“Evaluating Approaches to Diagnostic Test Regulation and the Impact of the FDA’s Proposed Rule.” Friends of Cancer Research’s President and CEO Dr. Jeff Allen, along with fellow healthcare leaders, testified at the House Energy and Commerce Health Subcommittee hearing, “Evaluating Approaches to Diagnostic Test Regulation and the Impact of the FDA’s Proposed Rule.” The hearing focused on…

February 1, 2024

Friends of Cancer Research Launches New Digital PATH Research Partnership

Friends of Cancer Research (Friends) is excited to announce the launch of a new research partnership, Digital and Computational Pathology Tool Harmonization (Digital PATH) Project. This project will identify factors that may contribute to variability in biomarker assessment across computational pathology platforms, propose areas for alignment in the field, and provide insights for shaping regulatory…

January 8, 2024

Friends of Cancer Research Announces Election of Dr. Roy Herbst to Board of Directors

Friends of Cancer Research (Friends) is honored to announce the addition of Roy S. Herbst, MD, PhD, Deputy Director of Yale Cancer Center and Smilow Cancer Hospital and Assistant Dean for Translational Research at Yale School of Medicine, to its Board of Directors. Dr. Herbst is a nationally recognized expert in lung cancer treatment and…

December 12, 2023

Friends of Cancer Research New Manuscript Shows Oncology Drugs Require Additional Dose Optimization After Approval

A new manuscript by Friends of Cancer Research (Friends) published today in AACR’s Clinical Cancer Research, shows that a substantial number of oncology drugs undergo additional dose evaluation after approval through Postmarketing Requirements (PMRs), studies that sponsors are required to conduct after approval to gather additional information about a product’s safety and/or efficacy. These findings…

Most read